• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
DENG Yanting,XIE Zhuohua,DENG Jiasheng,FANG Yibin,ZHANG Xinru,CHEN Jeiyi,YE Xiaoxue,ZHOU Zhipin.Progress in the application of transcriptomics and metabolomics in the study of traditional Chinese medicine prevention and treatment of liver fibrosis[J].Journal Of Pharmaceutical Research,2026,45(5):562-569,595[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1530times   Download 728次 QR Code for this article
Scan with your phone!
转录组学与代谢组学在中药防治肝纤维化研究中的应用进展
邓艳婷1,谢焯华1,邓家升1,方怡镔2,张心如2,陈洁怡2,叶晓雪3,周至品3
Font:Larger+|Default|Smaller-
(1.广西中医药大学药学院,广西 南宁 530001;2.广西医科大学药学院,广西 南宁 530021;3.广西医科大学附属柳州市人民医院,广西 柳州 545006)
摘要:
肝纤维化是慢性肝病进展至肝硬化和肝癌的关键可逆阶段,而当前临床治疗手段仍然十分有限。中医药凭借其多成分、多靶点、整体调节的特点,在防治肝纤维化方面显示出巨大潜力,然而其复杂的作用机制尚不明确。近年来,转录组学、代谢组学技术的发展,为揭示中药多靶点作用机制提供了不同视角,其全面性、整体性和系统性特点,与中医药的“整体思想”“辨证论治”契合,弥补了单个靶点、通路解释中药“整体调控”的局限性。本文综述了转录组学、代谢组学及联合应用在中药防治肝纤维化中的应用,以期为中药抗肝纤维化的研究与新药研发提供理论依据和新的策略。
关键词:  转录组学  代谢组学  中药  肝纤维化  研究进展
DOI:10.13506/j.cnki.jpr.2026.05.012
基金项目:广西中医药管理局自筹经费科研课题项目(No.GXZYB20230522)
Received Date:July 29, 2025   Revision Date:September 26, 2025   Publication Date:May 29, 2026
Progress in the application of transcriptomics and metabolomics in the study of traditional Chinese medicine prevention and treatment of liver fibrosis
DENG Yanting1,XIE Zhuohua1,DENG Jiasheng1,FANG Yibin2,ZHANG Xinru2,CHEN Jeiyi2,YE Xiaoxue3,ZHOU Zhipin3
(1. Pharmaceutical College, Guangxi University of Chinese Medicine, Nanning 530001, China; 2. Pharmaceutical College, Guangxi Medical University, Nanning 530021, China; 3. Liuzhou People′s Hospital Affiliated to Guangxi Medical University, Liuzhou 545006, China)
Abstract:
Liver fibrosis is a critical reversible stage in the progression of chronic liver disease to cirrhosis and liver cancer, yet current clinical treatment options remain highly limited. Traditional Chinese medicine (TCM), with its multi-component, multi-target, and holistic regulatory characteristics, has demonstrated significant potential in preventing and treating liver fibrosis. However, its complex mechanisms of action are still not fully understood. In recent years, advances in transcriptomics and metabolomics have provided new perspectives for elucidating the multi-target mechanisms of TCM. The comprehensive, holistic, and systematic nature of these omics technologies aligns with the “holistic philosophy” and “treatment based on syndrome differentiation” principles of TCM, thereby overcoming the limitations of single-target or single-pathway explanations for the “overall regulation” of TCM. This review summarizes the applications of transcriptomics, metabolomics, and their integrated use in TCM for the prevention and treatment of liver fibrosis, aiming to provide a theoretical basis and novel strategies for research and drug development in this field.
Key words:  Transcriptomics  Metabolomics  Traditional Chinese medicine  Liver fibrosis  Research progress
Today's Visits:458    Total Visits:2383149
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.